Ads
related to: prostate cancer hormone therapy prognosis options mayo clinic reviews- Contact Us
Get in contact with a sales
representative.
- Sign Up for Updates
Sign up for updates including new
imaging locations and savings.
- Review Case Studies
Discover case study results
for an imaging agent.
- Downloadable Resources
Discover downloadable guides for
health care professionals.
- Contact Us
Search results
Results from the WOW.Com Content Network
Management of prostate cancer. Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination.
Five-year survival rates range from 30–99%, depending on stage. [1] Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA ...
Androgen deprivation therapy. Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones ...
STAMPEDE (clinical trial) Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, over 10,000 participants had joined the trial.
Degarelix. Degarelix, sold under the brand name Firmagon among others, is a hormonal therapy used in the treatment of prostate cancer. [3][5] Testosterone is a male hormone that promotes growth of many prostate tumours and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management ...
The Prostate Adenocarcinoma: TransCutaneous Hormones ( PATCH) study is a large randomized controlled trial in the United Kingdom of high-dose transdermal estradiol patches versus gonadotropin-releasing hormone agonist therapy in the treatment of prostate cancer in men. [1] [2] [3] It is specifically comparing three to four 100 μg/day estradiol ...
Ads
related to: prostate cancer hormone therapy prognosis options mayo clinic reviews